RT Journal Article
SR Electronic
T1 SARS CoV-2 Serosurvey in Addis Ababa, Ethiopia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.23.20137521
DO 10.1101/2020.06.23.20137521
A1 Kempen, John H.
A1 Abashawl, Aida
A1 Kinfemichael, Hilkiah
A1 Difabachew, Mesfin Nigussie
A1 Kempen, Christopher J.
A1 Debele, Melaku Tesfaye
A1 Menkir, Abel A.
A1 Assefa, Maranatha T.
A1 Asfaw, Eyob H.
A1 Habtegabriel, Leul B.
A1 Addisie, Yohannes Sitotaw
A1 Nilles, Eric J.
A1 Longenecker, Joseph C.
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.23.20137521.abstract
AB The global COVID-19 pandemic caused by SARS CoV-2 is causing both mortality/morbidity and collateral social and economic damage related to public panic and aggressive public policy measures to contain the disease worldwide.(1) The epidemic appears to have taken hold much more slowly in sub-Saharan Africa than most of the world.(2) Antibody testing to evaluate the population proportion previously infected with SARS CoV-2 has the potential to guide public policy, but has not been reported so far for sub-Saharan Africa.Competing Interest StatementJohn H. Kempen serves as a consultant (DSMC Chair) for Gilead Sciences.Funding StatementFunding: Laboratory testing in the study was supported by International Clinical Laboratories, Addis Ababa, Ethiopia. Compliance expenses were paid by Massachusetts Eye and Ear, Boston, MA, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. MyungSung Medical College IRB 2. Partners Healthcare IRB 3. Addis Ababa Regional Health BureauAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available